Proxy Results Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported below under Item 5.07 of this Current Report, Moleculin Biotech, Inc., (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") at which the Company's stockholders approved the Moleculin Biotech, Inc. 2024 Stock Plan (the "2024 Plan"). For more information about the 2024 Plan, see the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on September 13, 2024 (the "Proxy Statement"), the relevant portions of which are incorporated herein by reference.

The foregoing description of the 2024 Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the 2024 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference.